Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	35.77	65.3	71.37	68.8	98.96	117.43
Short-Term Investments	80.57	131.15	195.32	162.07	19.89	15.11
Cash & Short-Term Investments	116.34	196.45	266.68	230.88	118.85	132.54
Cash Growth	-46.04%	-26.34%	15.51%	94.26%	-10.33%	-26.83%
Accounts Receivable	3.15	1.91	2.18	83.49	0.26	0.73
Other Receivables	-	1	2.31	0.96	0.38	0.02
Receivables	3.15	2.92	4.49	84.46	0.64	0.75
Prepaid Expenses	5.74	0.33	0.43	0.61	0.7	1.36
Other Current Assets	-	3	5.21	3.75	4.32	2.05
Total Current Assets	125.23	202.69	276.81	319.68	124.5	136.7
Property, Plant & Equipment	37.1	41.61	47.66	30	33.34	55.38
Long-Term Investments	32.48	5.24	65.7	-	-	-
Other Long-Term Assets	2.95	2.74	2.87	1.59	1.52	1.78
Total Assets	197.75	252.28	393.05	351.28	159.36	193.86

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.61	5.01	4	1.6	2.57	0.57
Accrued Expenses	7.95	12.1	14.17	16.82	7.82	10.95
Current Portion of Leases	6.88	7.84	7.23	3.2	2.83	5.57
Current Unearned Revenue	0.24	1.59	24.39	42.88	59.38	33.89
Total Current Liabilities	16.69	26.54	49.79	64.51	72.59	50.98
Long-Term Leases	25.69	28.66	36.5	17.09	20.29	38.61
Long-Term Unearned Revenue	-	-	6	32.36	6.45	8.21
Other Long-Term Liabilities	1	1	1	1	1	1
Total Liabilities	43.38	56.2	93.29	114.96	100.34	98.8

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.06	0.06	0.06	0.04	0.04	0.04
Additional Paid-In Capital	653.05	641.9	626.3	497.51	452.71	442.26
Retained Earnings	-498.32	-445.91	-326.18	-261.18	-393.51	-347.1
Comprehensive Income & Other	-0.42	0.03	-0.41	-0.05	-0.22	-0.14
Shareholders' Equity	154.38	196.08	299.76	236.32	59.02	95.06
Total Liabilities & Equity	197.75	252.28	393.05	351.28	159.36	193.86

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	32.57	36.5	43.73	20.29	23.13	44.18
Net Cash (Debt)	116.25	165.19	288.66	210.58	95.72	88.36
Net Cash Growth	-47.60%	-42.77%	37.08%	119.99%	8.33%	-33.83%
Net Cash Per Share	1.96	2.81	5.01	4.72	2.50	2.35
Filing Date Shares Outstanding	61.62	59.6	55.21	54.3	43.29	38.11
Total Common Shares Outstanding	61.27	59.05	54.73	44.04	38.61	37.92
Working Capital	108.54	176.15	227.02	255.18	51.91	85.72
Book Value Per Share	2.52	3.32	5.48	5.37	1.53	2.51
Tangible Book Value	154.38	196.08	299.76	236.32	59.02	95.06
Tangible Book Value Per Share	2.52	3.32	5.48	5.37	1.53	2.51
Machinery	-	23.35	22.67	23.16	22.01	21.91
Leasehold Improvements	-	6.85	6.49	7.11	12.55	15.7

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 9, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 23, 2026

Data Sources Report a data error